Clinical Trials

Accrual Status
Limit to SWOG Trials

1020 Results

Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2205

ICE COMPRESS: Randomized Trial of Limb Cryocompression versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuroropathy

Status Notes
This study is open to patient accrual effective 3/16/23 at 12 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
03-16-2023
ClinicalTrials.gov Registry Number
05642611
Open
Phase
Accrual
1%
SWOG Clinical Trial Number
S2302
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
EAY191-S3

Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors

Status Notes
This study is open to participant enrollment effective 12pm PT on 3/6/2023.
Research Committee(s)
comboMATCH
Immunomolecular Therapeutics
Activated
03-06-2023
ClinicalTrials.gov Registry Number
05554380
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Research Committee(s)
Lymphoma
Activated
02-23-2023
ClinicalTrials.gov Registry Number
05633615
Open
Phase
Accrual
0%
SWOG Clinical Trial Number
S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)

Status Notes
This study is open to participant accrual, effective January 17, 2023, at 12:00 p.m. Pacific Time.
Research Committee(s)
Symptom Control and Quality of Life
Activated
01-17-2023
Open
Phase
Accrual
5%
SWOG Clinical Trial Number
S2101

Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers

Status Notes
Activation: Effective October 14, 2022 at 12:00 PM Pacific Time
Research Committee(s)
iMATCH
Head and Neck Cancer
Melanoma
Early Therapeutics & Rare Cancers
Activated
10-14-2022
ClinicalTrials.gov Registry Number
NCT 05136196